Cardioxyl Pharmaceuticals has appointed Novartis’ Dr Shi Yin Foo as chief medical officer.
Dr Foo was responsible for the establishment and execution of multiple programmes in heart failure and the cardiorenal space at Novartis and will use her experience to lead research at US-based cardiovascular specialist Cardioxyl.
This experience includes time as a clinical and translational medicine reviewer for numerous studies from phase I to phase III clinical trials.
“Her unique combination of both early- and late-stage cardiovascular development experience combined with her extensive clinical experience in the treatment of patients with heart failure will serve as an excellent complement to Cardioxyl’s proprietary expertise in the biology, physiology and chemistry of nitroxyl donors,” said Dr Chris Kroeger, Cardioxyl’s president and CEO.
Dr Foo spent four years at Novartis from 2009 have joined the pharma company from her role as a physician at Massachusetts General Hospital in the US, where she specialised in cardiology.